ACUTE MYELOID LEUKEMIA

This early-stage study tested the safety of combining three drugs—uproleselan, azacitidine, and venetoclax—for older adults or those too frail for standard intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The goal was to see if this combination could …

This early-phase study tested the safety and initial effects of a new type of CAR-T cell therapy called LCAR-AMDR in a small group of patients with acute myeloid leukemia (AML) that had returned or not responded to standard treatments. The therapy involves collecting a patient's …

This was an early safety study for a new oral drug called SGR-2921. It aimed to find a safe and tolerable dose for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had returned or not responded to prior treatments. The main goal was to understand ho…

This early-stage study aimed to find a safe and effective dose of an experimental oral drug called Minnelide for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The trial enrolled 27 participants to determine the highest dose they …

This study tested an experimental cell therapy called TCB008 for adults with acute myeloid leukemia (AML) that has returned after treatment or did not respond to standard chemotherapy. The therapy involves infusing specially grown immune cells from healthy donors into patients af…

This early-stage study tested a new drug called DSP107, given alongside standard chemotherapy drugs, for people with advanced forms of blood cancer (AML and MDS) that had come back or stopped responding to previous treatments. The main goals were to find a safe dose and see if th…

This early-stage study tested the safety and initial effectiveness of a new drug, CWP232291, when given with the chemotherapy drug cytarabine. It was for adults whose acute myeloid leukemia (AML) had returned or did not respond to prior treatments. The trial was terminated early …

This study tested the safety and effectiveness of an experimental drug called MBG453 when given alongside two other drugs (azacitidine and venetoclax) to treat acute myeloid leukemia (AML). It was for adults newly diagnosed with AML who were considered unfit for intensive chemoth…

This study tested whether specially prepared immune cells from a stem cell donor could help patients with acute myeloid leukemia (AML) after their transplant. The cells, called MT-401, were given to try to prevent the cancer from coming back or to treat it if it did return. The t…

This early-stage study aimed to test the safety and initial effectiveness of a new drug called SL-172154. It was given alone or combined with standard drugs (azacitidine and/or venetoclax) to adults with higher-risk forms of myelodysplastic syndromes (MDS) or acute myeloid leukem…

This study tested how well two chemotherapy drugs, venetoclax and decitabine, work together to control aggressive blood cancers. It was for older adults newly diagnosed with acute myeloid leukemia (AML) or people whose AML or high-risk myelodysplastic syndrome (MDS) had returned …

This study tested a drug called sabatolimab, alone or with another drug, for people with acute myeloid leukemia (AML). The goal was to see if it could prevent the cancer from coming back in patients who had a small amount of leftover disease after a stem cell transplant. The tria…

This study tested whether adding a new drug called isatuximab to standard chemotherapy could help children whose acute leukemia had come back or not responded to previous treatment. It involved 67 children and young adults, from infants to under 18 years old. The main goal was to…

This study tested whether adding an experimental drug called siremadlin to two standard leukemia drugs could improve treatment responses for adults with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. It aimed to find a safe dose and see if the three-dr…

This study tested whether combining the drugs venetoclax with azacytidine or DA could prevent relapse in acute myeloid leukemia (AML) patients who still had small amounts of cancer cells after initial treatment. The goal was to see if this 'preemptive' treatment could keep patien…

This early-stage study tested a combination of two drugs, AZD1775 and belinostat, for patients with advanced blood cancers like acute myeloid leukemia (AML) that have returned or not responded to prior treatments. The main goal was to find the safest and most effective dose of th…